Understanding Subutex: Buprenorphine for Opioid Dependence Treatment in the UK

Subutex, a well-known brand of buprenorphine sublingual tablets, has played a significant role in the UK’s approach to managing opioid dependence. As part of medication-assisted treatment (MAT), it helps individuals overcome addiction to stronger opioids like heroin or prescription painkillers.

What is Subutex?

Composition and Form Subutex contains buprenorphine hydrochloride as its active ingredient. It is available as sublingual tablets (placed under the tongue to dissolve) in strengths such as 0.4 mg, 2 mg, and 8 mg. These white, uncoated tablets are designed for rapid absorption through the oral mucosa.

Buprenorphine is a partial opioid agonist. It binds to the same mu-opioid receptors in the brain as full agonists like heroin or morphine but activates them only partially. This produces enough effect to reduce cravings and withdrawal symptoms without delivering the intense euphoria or dangerous respiratory depression associated with stronger opioids.

How Subutex Works in Opioid Dependence Treatment

Note: In the United Kingdom, branded Subutex tablets have been discontinued by the manufacturer (Indivior) as of early 2026. Generic buprenorphine sublingual tablets remain available and serve the same purpose. Patients should consult their prescriber for switches to equivalent generics.